Two Directors at ABB Ltd sold 30,150 shares at 0.000USD. The significance rating of the trade was 77/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing ...
Philips reported a better-than-expected 2Q25 update. We increase our target price to €23 per share (from €21) but keep our Hold rating. The results are surprisingly volatile in our view with large quarterly fluctuations. We believe valuation is fair relative to peers given its lower growth and margin profile.
Allfunds Group PLC: Ready to Spring forward. Basic-Fit: 1H25 ahead of INGF, membership ingrowth, outlook reiterated, FCF a bit light. Lotus Bakeries: Preview 1H25. NN Group & ASR: Dutch Pension Reform not an issue at 29 October Dutch elections. Philips: 2Q25 results, much lower tariff impact. Proximus: New BICS CEO and Global CRO laid off. Vastned: Good results, EPRA EPS guidance up by 2.5%. Zabka: 2Q25 Preview
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: ACCIONA, ACCIONA ENERGÍA, CAF, ENDESA, IBERDROLA, UNICAJA. EUROPA: AIR LIQUIDE, ESSILORLUXOTTICA, PHILIPS. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 2T’25 que se publicarán en España y Europa en los próximos días. Tras el acuerdo… Europa termina en pérdidas La digestión del acuerdo comercial fue apagan...
Indonesia’s Ministry of Health and Philips to deliver nationwide coverage of advanced image-guided therapy systems in Indonesia, expanding access to cardiac, stroke and cancer care in all 38 provinces July 29, 2025 Long-term multiyear agreements will see Philips installing its advanced Azurion image-guided therapy systems nationwide across all provinces, including rural and remote areasInitiative brings minimally invasive care to millions of cardiac, stroke and cancer patients in IndonesiaCombines cutting-edge treatment technology, services and training to strengthen Indonesia’s health inf...
Philips builds strong order intake momentum and drives margin expansion in Q2 July 29, 2025 Q2 2025 Group Highlights Comparable order intake growth 6%Group sales EUR 4.3 billion, reflecting 1% increase in comparable salesIncome from operations EUR 400 millionAdjusted EBITA margin increased 130 bps to 12.4% of salesFree cash flow increased to EUR 230 millionPhilips increases full year 2025 outlook for Adjusted EBITA margin and free cash flow; reiterates comparable sales growth outlook Roy Jakobs, CEO of Royal Philips:“We are focused on driving profitable growth and delivering better care ...
Philips announces collaboration with Epic to enhance ambulatory cardiac monitoring July 24, 2025 Philips will now offer the largest cardiac care portfolio through Epic’s Aura platform CAMBRIDGE, Mass. – (NYSE: PHG, AEX: PHIA) a global leader in health technology, today announced a collaboration with to integrate Philips’ suite of cardiac ambulatory monitoring and diagnostics services with Aura, the specialty diagnostics suite of the leading electronic health record (EHR) company. This collaboration will offer the broadest cardiac care portfolio of any single service provider integrating...
Philips advances minimally invasive therapy procedures in prostate cancer care with FDA 510(k) clearance for image-guided navigation technology July 23, 2025 Supporting prostate cancer diagnosis with more precise guidance for clinicians, offering better patient care Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced a major advancement in image-guided navigation for prostate cancer care with the FDA 510(k) clearance of the latest . The system includes a new advanced annotation [1] workflow that supports clinicians during focal thera...
ASM International: 2Q25 Results; Positive tone, weak orders. CM.com: 1H25 results; disappointing performance, guidance downgrade. Gimv: Gimv fuels Hemink's sustainable expansion. KPN: Solid 2Q25, guidance raised largely on €25m IPR claim benefit. Philips: 2Q25 Preview; improvement needed. Randstad: 2Q25 in line; outlook touch below; FX spoils the party but operational leverage story is unfolding. Sofina: Newsletter #16. Universal Music Group: EU opens in-depth investigation into Downtown ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.